
Amgen
OrganizationHeard in 64 episodes across 21 shows since Nov 2025
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. It discovers, develops, manufactures, and delivers biologic medicines for serious diseases, using biology and technology to address major unmet medical needs.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Amgen per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 27 | 0.01‰ | 1 |
| Sep 8 | 0.08‰ | 7 |
| Sep 9 | 0.09‰ | 1 |
| Sep 12 | 0.11‰ | 2 |
| Sep 13 | 0.12‰ | 1 |
| Sep 14 | 0.12‰ | 1 |
| Sep 28 | 0.02‰ | 2 |
| Oct 1 | 0.03‰ | 1 |
| Oct 7 | 0.02‰ | 1 |
| Oct 22 | 0.02‰ | 3 |
| Oct 23 | 0.03‰ | 1 |
| Oct 26 | 0.07‰ | 4 |
| Oct 27 | 0.07‰ | 1 |
| Oct 28 | 0.08‰ | 1 |
| Oct 30 | 0.07‰ | 2 |
| Oct 31 | 0.08‰ | 1 |
| Nov 3 | 0.04‰ | 1 |
| Nov 4 | 0.07‰ | 4 |
| Nov 6 | 0.06‰ | 1 |
| Nov 11 | 0.02‰ | 2 |
| Nov 20 | 0.01‰ | 1 |
Email alert
Email me when Amgen comes up on a podcast
One email a week at most, with the new episodes that mention Amgen. Free, no account needed, unsubscribe in one click.
What experts have said about Amgen
22 statements · 16 positive · 4 negative · 1 mixed · 1 neutral
Amgen’s phase three Sjögren’s trial produced very strong results.
“Amgen sort of hit it out of the ballpark in the phase three”
Open the episode · Episode 202 - November 6, 2026Listen at 55:00
Amgen will probably file its obesity pen application in the second half of next year if successful.
“they're probably going to be filing assuming success in the second half of next year with the pen.”
Open the episode · Episode 202 - November 6, 2026Listen at 55:58
Amgen is a value investment yielding approximately 6%.
“this is a value play that pays you 6%”
Open the episode · Cracks In The AI Trade… And AMD Reports Results 11/3/26Listen at 20:12
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
64 episodes featuring Amgen, newest first
- Nov 20, 2026
AI valuations collide with inflation and market riskMad Money w/ Jim CramerNov 20, 2026 - Nov 13, 2026
Biotech launches expose the gap between forecasts and adoptionBiotech HangoutNov 13, 2026 - Nov 11, 2026
CoreWeave tests whether AI stocks can sustain their reboundHalftime ReportNov 11, 2026 - Nov 11, 2026
Ro bets healthcare’s future on patient demand and softwareInvest Like the Best with Patrick O'ShaughnessyNov 11, 2026 - Nov 6, 2026
Election stakes meet biotech’s regulatory and pipeline risksBiotech HangoutNov 6, 2026 - Nov 6, 2026
AI’s market reckoning meets jobs, robotics and biotech’s next phaseTBPNNov 6, 2026